Drug Profile


Alternative Names: H4R antagonist; Histamine 4 Receptor antagonist; JNJ-168; JNJ-38518168; JNJ-38518168-ZBQ

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Developer Janssen Research & Development
  • Class Antiasthmatics; Antihistamines; Antipruritics; Antipsoriatics; Antirheumatics; Benzimidazoles; Diaminopyrimidines; Piperidines; Small molecules
  • Mechanism of Action Histamine H4 receptor antagonists; Th1 cell modulators; Th17 cell modulators; Th2 cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma; Plaque psoriasis; Rheumatoid arthritis
  • No development reported Pruritus

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Rheumatoid-arthritis(In volunteers) in Belgium (PO, Liquid)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Pruritus in USA
  • 03 Mar 2016 Phase-II clinical trials in Plaque psoriasis in Poland (PO) (NCT02295865)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top